European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changing the treatment landscape for this aggressive disease”, said Levi Ga...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changing the treatment landscape for this aggressive disease”, said Levi Ga...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news
Ontario should vaccinate newborns for hepatitis B, study suggests
(Canadian Medical Association Journal) Not all pregnant women are universally screened for hepatitis B virus (HBV) in Ontario, even though this screening is recommended, and the majority of those who test positive do not receive follow-up testing or interventions, leading to infections of newborns, found new research in CMAJ (Canadian Medical Association Journal). (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 26, 2020 Category: Infectious Diseases Source Type: news
Qui én realmente necesita la vacuna de hepatitis B
¿Quiénes realmente necesitan la vacuna de hepatitis B? ... Las personas con diabetes tienen el doble de probabilidad de infectarse con hepatitis B, una enfermedad grave y mortal que afecta el hígado. (Source: AARP.org News)
Source: AARP.org News - October 24, 2020 Category: American Health Source Type: news
HIV Drugs Prevent Type 2 Diabetes, May Be Path to New Therapy HIV Drugs Prevent Type 2 Diabetes, May Be Path to New Therapy
An analysis of five databases shows that the NRTIs used to treat HIV and hepatitis B infection are able to prevent diabetes by blocking inflammasone activation; discovery may pave way for new therapeutics.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 22, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
3 Win Nobel Medicine Prize for Discovering Hepatitis C Virus
(STOCKHOLM) — Americans Harvey J. Alter and Charles M. Rice and British-born scientist Michael Houghton won the Nobel Prize for medicine on Monday for their discovery of the hepatitis C virus, a major source of liver disease that affects millions worldwide.
Announcing the prize in Stockholm, the Nobel Committee noted that the trio’s work identified a major source of blood-borne hepatitis that couldn’t be explained by the previously discovered hepatitis A and B viruses. Their work, dating back to the 1970s and 1980s, has helped saved millions of lives, the committee said.
“Thanks to their discovery, ...
Source: TIME: Science - October 5, 2020 Category: Science Authors: DAVID KEYTON and FRANK JORDANS / AP Tags: Uncategorized News News Desk wire Source Type: news
Chemical Abstracts indexes two journals
Hepatitis B Annual and Asian Journal of Transfusion Sciences have been included in Chemical Abstracts by the Chemical Abstracts Service.December-2007 (Source: Medknow News)
Source: Medknow News - September 30, 2020 Category: Databases & Libraries Source Type: news
SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Global Head, Jans...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news
After big buyout, team looks to lead hepatitis B, NASH drug maker to $100M IPO
Two-year-old Aligos Therapeutics Inc. is seeking a $100 million initial public offering to help take its experimental chronic hepatitis B drugs into clinical trials.
The South San Francisco company is the work of much of the executive team that translated $74 million in investments for hepatitis C-focused Alios BioPharma Inc. of South San Francisco into a $1.75 billion cash deal in 2014 with Johnson& Johnson's (NYSE: JNJ) Janssen Pharmaceutical unit.
Janssen ultimately dumped Alios' oral drug,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 28, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
After big buyout, team looks to lead hepatitis B, NASH drug maker to $100M IPO
Two-year-old Aligos Therapeutics Inc. is seeking a $100 million initial public offering to help take its experimental chronic hepatitis B drugs into clinical trials.
The South San Francisco company is the work of much of the executive team that translated $74 million in investments for hepatitis C-focused Alios BioPharma Inc. of South San Francisco into a $1.75 billion cash deal in 2014 with Johnson& Johnson's (NYSE: JNJ) Janssen Pharmaceutical unit.
Janssen ultimately dumped Alios' oral drug,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news
Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expected from ...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news
Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expected from ...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news
The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins.
Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news
Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia
SUZHOU, China and ROCKVILLE, Md., Sept. 7, 2020 -- (Healthcare Sales & Marketing Network) -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),... Biopharmaceuticals, Oncology, FDA Ascentage Pharma, APG-2575, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2020 Category: Pharmaceuticals Source Type: news
